Skip to main
AYTU

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. presents an attractive valuation, as indicated by a net present value (NPV) analysis that suggests significant upside potential from its current share price. The company's clinical trials for EXXUA, involving over 5,000 patients, have shown promising improvements in depression symptoms with minimal side effects, highlighting the therapeutic's potential success. Additionally, the anticipated launch of the EXXUA drug for major depressive disorder (MDD) in the fourth quarter of 2025 is expected to act as a strong catalyst for the company's stock performance.

Bears say

Aytu BioPharma reported a revenue decline of 16% year-over-year, amounting to $13.9 million, which raises concerns about the company's financial stability and growth trajectory. Despite the claim of significant upside potential based on future sales estimates, the current financial performance suggests deeper underlying issues that may hinder investor confidence. Additionally, while the market for antidepressants continues to expand, Aytu's position in addressing unmet needs through its pipeline may not be sufficient to counterbalance the immediate challenges related to declining revenues and potential market competition.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.